Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pitolisant in children and adolescents with narcolepsy
NL-OMON53057Phase 3Active, not recruiting
- Sponsor
- Bioprojet
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pitolisant in narcolepsy and narcolepsy type 1 (NT1) (3 arms), sponsored by Bioprojet. Primary endpoint: Primary efficacy endpoint. Started Sep 2017; status: active, not recruiting.
02
Drugs
pitolisant
03
Conditions
narcolepsynarcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NL-OMON53057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53057.